Altimmune (ALT) Competitors $4.76 -0.14 (-2.86%) Closing price 03:57 PM EasternExtended Trading$4.74 -0.02 (-0.53%) As of 04:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALT vs. BHC, GMTX, APLS, ARWR, TWST, VCEL, KNSA, NAMS, DNLI, and RXRXShould you be buying Altimmune stock or one of its competitors? The main competitors of Altimmune include Bausch Health Cos (BHC), Gemini Therapeutics (GMTX), Apellis Pharmaceuticals (APLS), Arrowhead Pharmaceuticals (ARWR), Twist Bioscience (TWST), Vericel (VCEL), Kiniksa Pharmaceuticals International (KNSA), NewAmsterdam Pharma (NAMS), Denali Therapeutics (DNLI), and Recursion Pharmaceuticals (RXRX). These companies are all part of the "pharmaceutical products" industry. Altimmune vs. Its Competitors Bausch Health Cos Gemini Therapeutics Apellis Pharmaceuticals Arrowhead Pharmaceuticals Twist Bioscience Vericel Kiniksa Pharmaceuticals International NewAmsterdam Pharma Denali Therapeutics Recursion Pharmaceuticals Bausch Health Cos (NYSE:BHC) and Altimmune (NASDAQ:ALT) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings. Is BHC or ALT more profitable? Bausch Health Cos has a net margin of -0.41% compared to Altimmune's net margin of -451,200.00%. Altimmune's return on equity of -65.44% beat Bausch Health Cos' return on equity.Company Net Margins Return on Equity Return on Assets Bausch Health Cos-0.41% -540.45% 5.26% Altimmune -451,200.00%-65.44%-58.43% Which has more volatility and risk, BHC or ALT? Bausch Health Cos has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, Altimmune has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500. Which has preferable earnings and valuation, BHC or ALT? Bausch Health Cos has higher revenue and earnings than Altimmune. Bausch Health Cos is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBausch Health Cos$9.63B0.27-$46M-$0.11-63.17Altimmune$20K19,304.18-$95.06M-$1.26-3.78 Does the media favor BHC or ALT? In the previous week, Altimmune had 4 more articles in the media than Bausch Health Cos. MarketBeat recorded 12 mentions for Altimmune and 8 mentions for Bausch Health Cos. Bausch Health Cos' average media sentiment score of 0.61 beat Altimmune's score of 0.10 indicating that Bausch Health Cos is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch Health Cos 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Altimmune 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders hold more shares of BHC or ALT? 78.7% of Bausch Health Cos shares are held by institutional investors. Comparatively, 78.1% of Altimmune shares are held by institutional investors. 8.1% of Bausch Health Cos shares are held by company insiders. Comparatively, 4.1% of Altimmune shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts prefer BHC or ALT? Bausch Health Cos presently has a consensus price target of $7.42, suggesting a potential upside of 6.73%. Altimmune has a consensus price target of $19.00, suggesting a potential upside of 299.16%. Given Altimmune's stronger consensus rating and higher possible upside, analysts clearly believe Altimmune is more favorable than Bausch Health Cos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bausch Health Cos 1 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.86Altimmune 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00 SummaryAltimmune beats Bausch Health Cos on 9 of the 17 factors compared between the two stocks. Get Altimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALT vs. The Competition Export to ExcelMetricAltimmuneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$386.08M$2.42B$5.49B$9.01BDividend YieldN/A1.77%5.39%4.11%P/E Ratio-3.788.9827.4320.06Price / Sales19,304.18476.19397.78108.02Price / CashN/A151.5836.1356.90Price / Book2.744.638.085.67Net Income-$95.06M$31.34M$3.16B$248.47M7 Day Performance31.86%0.84%2.13%2.90%1 Month Performance-12.18%7.92%4.44%5.75%1 Year Performance-27.88%1.88%35.63%21.36% Altimmune Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALTAltimmune2.3093 of 5 stars$4.76-2.9%$19.00+299.2%-27.3%$386.08M$20K-3.7850BHCBausch Health Cos3.2721 of 5 stars$6.11-1.1%$7.42+21.4%+0.0%$2.26B$9.73B-55.5520,700GMTXGemini TherapeuticsN/A$51.61+3.0%N/A+10.0%$2.24BN/A-51.6130High Trading VolumeAPLSApellis Pharmaceuticals4.5231 of 5 stars$17.62-0.4%$40.05+127.3%-49.1%$2.21B$775.84M-9.84770Trending NewsAnalyst ForecastAnalyst RevisionARWRArrowhead Pharmaceuticals3.9262 of 5 stars$15.51+1.2%$43.71+181.8%-33.0%$2.14B$3.55M-11.08400TWSTTwist Bioscience4.3966 of 5 stars$35.33+2.0%$50.40+42.7%-20.4%$2.12B$347.68M-10.87990News CoveragePositive NewsVCELVericel2.8916 of 5 stars$41.80-0.5%$61.14+46.3%-8.0%$2.10B$237.22M1,393.80300KNSAKiniksa Pharmaceuticals International3.6962 of 5 stars$28.72+1.0%$38.80+35.1%+48.7%$2.10B$423.24M-114.88220NAMSNewAmsterdam Pharma3.0459 of 5 stars$18.21+1.4%$42.89+135.5%-6.6%$2.04B$45.56M-9.694Positive NewsDNLIDenali Therapeutics4.5383 of 5 stars$13.62-1.9%$33.71+147.5%-31.5%$1.98B$330.53M-5.10430RXRXRecursion Pharmaceuticals2.0782 of 5 stars$4.83-4.0%$7.00+44.9%-27.2%$1.96B$58.84M-2.73400Analyst Forecast Related Companies and Tools Related Companies Bausch Health Cos Alternatives Gemini Therapeutics Alternatives Apellis Pharmaceuticals Alternatives Arrowhead Pharmaceuticals Alternatives Twist Bioscience Alternatives Vericel Alternatives Kiniksa Pharmaceuticals International Alternatives NewAmsterdam Pharma Alternatives Denali Therapeutics Alternatives Recursion Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALT) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Altimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
